Petros Pharmaceuticals, Inc. (PTPI) Form 8-K — Jun 18, 2026
Mitchell Arnold has mutually separated from his roles as Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer of Petros Pharmaceuticals, Inc., effective June 18, 2026. The company entered into a General Release and Severance Agreement providing Mr. Arnold with severance of $38,500, acceleration of 3,000 unvested shares, and two months of COBRA premium payments. To ensure continuity, the board of directors immediately appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer.
Key figures
- Tax Gross Up
- 100
- Severance Amount
- 38500
- Shares Accelerated
- 3000
- Cobra Duration Months
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.